TMO

Thermo Fisher Scientific
D

TMO

Arincen67/100B

Thermo Fisher Scientific free cash flow 1989–2026

Thermo Fisher Scientific's free cash flow in Q3 FY2026, the three months to 26 September 2026, was 2.11B USD, up 15.1% on the same quarter a year before. Thermo Fisher Scientific's free cash flow over the last twelve months was 7.60B USD, up 24.3% on the twelve months before. In fiscal year 2025 it was 6.29B USD, down 13.4% on the year before.

Last updated 3 Nov 2026 · Next report 4 Feb 2027

Free cash flow

Free cash flow · +10.1% a year over 10 yearsFree cash flow margin

Growth

Fiscal yearPeriod endingFree cash flowGrowthFree cash flow marginOperating cash flowCapital expenditureFree cash flow per share
TTM26 Sept 20267.60B+24.30%16.04%9.32B-1.73B20.36
FY202531 Dec 20256.29B-13.40%14.12%7.82B-1.53B16.69
FY202431 Dec 20247.27B+4.91%16.95%8.67B-1.40B18.97
FY202331 Dec 20236.93B+0.23%16.16%8.41B-1.48B17.85
FY202231 Dec 20226.91B-1.55%15.39%9.15B-2.24B17.54
FY202131 Dec 20217.02B+3.01%17.90%9.54B-2.52B17.68
FY202031 Dec 20206.82B+68.40%21.15%8.29B-1.47B17.08
FY201931 Dec 20194.05B+6.92%15.84%4.97B-926.00M10.04
FY201831 Dec 20183.79B+8.24%15.54%4.54B-758.00M9.32
FY201731 Dec 20173.50B+28.95%16.72%4.01B-508.00M8.79
FY201631 Dec 20162.71B+13.28%14.84%3.16B-444.40M6.82
FY201531 Dec 20152.39B+9.22%14.11%2.82B-422.90M5.96
FY201431 Dec 20142.19B+26.83%12.98%2.62B-427.60M5.45
FY201331 Dec 20131.73B+0.23%13.20%2.01B-282.40M4.72
FY201231 Dec 20121.72B+21.05%13.78%2.04B-315.10M4.70
FY201131 Dec 20111.42B+15.60%12.15%1.69B-266.50M3.70
FY201031 Dec 20101.23B-15.11%11.42%1.50B-265.50M3.01
FY200931 Dec 20091.45B+25.60%14.36%1.66B-207.50M3.43
FY200831 Dec 20081.16B-11.64%11.01%1.42B-264.40M2.66
FY200731 Dec 20071.31B+297.74%13.42%1.48B-175.50M2.95
FY200631 Dec 2006328.86M+44.64%8.67%405.65M-76.80M1.61
FY200531 Dec 2005227.37M+5.99%8.64%270.91M-43.55M1.38
FY200431 Dec 2004214.53M+25.76%9.72%264.51M-49.99M1.28
FY200331 Dec 2003170.58M+230.08%8.13%216.72M-46.14M1.00
FY200231 Dec 200251.68M-50.12%2.48%102.89M-51.21M0.29
FY200131 Dec 2001103.60M-17.70%4.73%188.40M-84.80M0.56
FY200031 Dec 2000125.88M—5.52%199.92M-74.04M0.77
FY199931 Dec 1999-150.88M—-6.11%337.12M-488.00M-0.95
FY199831 Dec 1998-72.70M—-1.88%328.50M-401.20M-0.43
FY199731 Dec 1997-691.70M-791.70%-19.44%269.00M-960.70M-4.07
FY199631 Dec 1996100.00M-24.07%3.41%224.50M-124.50M0.57
FY199531 Dec 1995131.70M-8.54%5.97%194.60M-62.90M0.83
FY199431 Dec 1994144.00M+105.42%9.08%204.20M-60.20M0.99
FY199331 Dec 199370.10M—5.61%126.70M-56.60M0.65
FY199231 Dec 1992-5.10M—-0.54%54.90M-60.00M-0.06
FY199131 Dec 1991-10.50M—-1.30%23.00M-33.50M-0.12
FY199031 Dec 1990-101.40M—-14.32%18.60M-120.00M-1.44
FY198931 Dec 1989-300.00K—-0.05%47.60M-47.90M-0.00

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Stock buybacks,Cash flow

Common questions about Thermo Fisher Scientific's free cash flow

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.